Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).

Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, Gage FH, Johnson EM Jr, Bartus RT.

Neurobiol Dis. 2013 Oct;58:38-48. doi: 10.1016/j.nbd.2013.04.011.

PMID:
23631873
2.

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.

Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM Jr, Kordower JH, Herzog CD.

Neurobiol Dis. 2011 Oct;44(1):38-52. doi: 10.1016/j.nbd.2011.05.026.

PMID:
21704161
3.

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.

Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, Cunningham JJ, Printz MA, Kordower JH, Bartus RT.

Neurobiol Dis. 2007 Jul;27(1):67-76.

PMID:
17532642
5.

Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.

Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, Kaufman D, Chen AF.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):155-61.

PMID:
15790539
7.

GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A.

Brain. 2011 Aug;134(Pt 8):2302-11. doi: 10.1093/brain/awr149.

PMID:
21712347
8.

Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.

Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC.

Gene Ther. 1999 Dec;6(12):1936-51.

9.

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies.

Bartus RT, Kordower JH, Johnson EM Jr, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog CD.

Neurobiol Dis. 2015 Jun;78:162-71. doi: 10.1016/j.nbd.2015.03.023.

PMID:
25841760
10.
11.
13.

Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

Choi-Lundberg DL, Lin Q, Schallert T, Crippens D, Davidson BL, Chang YN, Chiang YL, Qian J, Bardwaj L, Bohn MC.

Exp Neurol. 1998 Dec;154(2):261-75.

PMID:
9878166
14.

Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.

Connor B, Kozlowski DA, Unnerstall JR, Elsworth JD, Tillerson JL, Schallert T, Bohn MC.

Exp Neurol. 2001 May;169(1):83-95.

PMID:
11312561
16.
17.

Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.

Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC.

Exp Neurol. 2000 Nov;166(1):1-15.

PMID:
11031079
20.

Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Gombash SE, Manfredsson FP, Mandel RJ, Collier TJ, Fischer DL, Kemp CJ, Kuhn NM, Wohlgenant SL, Fleming SM, Sortwell CE.

Gene Ther. 2014 Jul;21(7):682-93. doi: 10.1038/gt.2014.42.

Items per page

Supplemental Content

Support Center